Menlo Therapeutics Announces Results from a Phase 2 Trial of Serlopitant for Pruritus Associated with Atopic Dermatitis Pharmaceutical Investing
Xanthic Biopharma Inc. Receives Conditional Listing Approval from the Canadian Securities Exchange Cannabis Investing News
EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 Pharmaceutical Investing
Aclaris Therapeutics Partners with Cipher Pharmaceuticals to seek regulatory approval and commercialize A-101 40% topical solution Pharmaceutical Investing
Sorrento and Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With Relapsed or Refractory Multiple Myeloma Pharmaceutical Investing
VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder Biotech Investing
Evolus Phase III European – Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox® Meets Primary Endpoint Longevity Investing
